Compare Gilead Sciences, Inc. (GILD) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard Ultra Short Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | VUSB | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $50.03 |
52-Week Low | $110.56 | $49.60 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VUSB trades at $49.66, up 0.04% on the day, with a bearish technical signal driven by moving averages and ADX readings. Recent dividends include $0.18 paid on July 6, 2026, and $0.17 scheduled for August 5, 2026. Financial ratios such as P/E and ROE are unavailable in the current data, limiting fundamental assessment.
The outlook is cautious due to bearish technical indicators and incomplete financial data. Risks include interest rate sensitivity, as highlighted by recent Fed commentary, and reliance on short-term bond performance. Investors should await updated financial disclosures for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
